medigraphic.com
Colegio de Medicina Interna de México.

2010, Number 5

<< Back Next >>

Med Int Mex 2010; 26 (5)

Severe pneumonia virus H1N1: a review of the literature apropos of a case. Current affairs

Martha Gabriela Márquez, Mayra Sofía Castro, Asisclo de Jesús Villagómez, Saúl Hernández

Language: Spanish
References: 20
Page: 516-523
PDF size: 475.91 Kb.


ABSTRACT

Influenza is an acute respiratory disease, highly contagious, most important in the history of mankind. A new strain of greater importance emerged type A subtype H1N1 strain S-OIV. Influenza is caused by the family Orthomixovirus (Greek ortho: law and myxo: mucins, mucus) which has a single genus: that of the influenza virus, including types A, B and C. Its mechanism of transmission is from person to person, person-fomit-person, from one day before symptoms until 3 to 7 days later. The incubation period is over four days with a mean of 1.4 days (95% CI, 1.3 to 1.5). The virus invades the epithelial cells of the airway by activating complex antigen / antibody, binds to receptors formed by mucus sialic acid molecules and producing replication viral.7 WHO declared AH1N1 influenza pandemic in June 2009. Until January 24 2010 worldwide there are more than 209 countries and territories or communities that have reported cases of influenza and at least 14771 deaths worldwide. 70,044 In Mexico AH1N1 confirmed cases of fluenza and 995 deaths. The organization expressed its confidence in the vaccine, calling it the most important tool against pandemia. The Infectious Diseases Society of America (IDSA) published in April 2009 the new guidelines on diagnosis, treatment and chemoprophylaxis of influenza estacional. The emergence of different viruses resistant to antiviral traditional presents a challenge for optimal clinical management and prompt and adecuado. We report a case of severe pneumonia patient with more severe ARDS by influenza A virus H1N1.


REFERENCES

  1. Zimmer SM, Burke DS. Historical perspective: emergence of influenza A (H1N1) viruses. N Engl J Med 2009;361:279-285.

  2. Fajardo DG, Hernández TF, Santacruz JV, Suárez JR, y col. Perfil epidemiológico de la mortalidad por influenza humana A (H1N1) en México. Salud Pública Mex 2009;51:361-371.

  3. Kou Z, Hu SN, Li TX. Genome evolution of novel influenza A (H1N1) viruses in human. Chinese Sci Bull 2009;54:2159-2163.

  4. Chowell G, Bertozzi SM, et al. Severe respiratory disease concurrent with the circulation of H1N1 Influenza. N Engl J Med 2009;361:674-679.

  5. Rothberg MB, Haessler SD. Complications of seasonal and pandemic Influenza. Crit Care Med 2010;38 (suppl.): DOI: 10.1097/CCM.0b013e3181c92eeb.

  6. Guidelines for preventing health care-associated Pneumonia. Recommendations of CDC and Healthcare Infection Control Practices Advisor Committee. 2003. www.cdc.gov/mmwr/ preview/mmwrhtml/rr5303a1.htm

  7. Marshall JC, Reinhart K. Biomarkers of sepsis. Crit Care Med 2009;37:2290-2298.

  8. Meunier I, Pillet S, Simonsen N, et al. Influenza Pathogenesis: Lessons learned from animal studies with H5N1, H1N1 Spanish, and pandemic H1N1 2009 influenza. Crit Care Med 2010;38[suppl]:S1-S9.

  9. Datos importantes sobre la influenza o gripe estacional. Departamento de Salud y Servicios Humanos. Centro para el Control y la Prevención de Enfermedades. www.cdc.gov/flu/espanol

  10. Louie J, Acosta M, Winter K, et al. Factors associated with death or hospitalization due to pandemic 2009 Influenza A (H1N1) infection in California. JAMA 2009;302(17):1896-1902.

  11. Beigel JH. Influenza. Concise Definitive Review. Crit Care Med 2008;36;2660-2666.

  12. NHS. Department of Health. Critical care strategy: Managing the H1N1 flu pandemic September 2009. http://www.dh.gov. uk/en/publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/ DH_104977.

  13. ¿Cómo se comporta la epidemia de influenza A (H1N1) en México? http://promocion.salud.gob.mx/dgs/descargas1/ influenza/mat/boletin_como_se_comporta_la_ EPIDEMIA_20enero2010.pdf

  14. Patel M, Dennis A, et al. Pandemic (H1N1) 2009 influenza. Br J Anaesth 2010; 104:128-142.

  15. Kumar A, Zarychanski R. Critically lll patients with 2009 influenza A (H1N1) infection in Canada. JAMA 2009;302(17):1872-1879.

  16. Smith J, Ariano RE, et al. The use of antiviral agents for the management of severe influenza. Crit Care Med 2010;38[suppl]:S000-S000.

  17. Schünemann HJ, Hill SR, et al. WHO rapid advice guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis 2007;7:21-31.

  18. Khazeni N, Bravata DM, Holty JE, Uyeki TM, et al. Systematic Re view: Safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal Influenza. Ann Intern Med 2009;151:464-473.

  19. Acciones básicas ante la intensificación de la transmisión de influenza. Secretaría de Salud, 24 de Abril de 2009. http://promocion. salud.gob.mx/dgs/interior1/influenza_estacional.html

  20. Restrepo MI, Anzueto A. Severe Community. Acquired Pneumonia. Infect Dis Clin N Am 2009;23:503-520.




2020     |     www.medigraphic.com